Radioiodine News and Research

RSS

Iodine-131 (131I), also called radioiodine (though many other radioactive isotopes of this element are known), is an important radioisotope of iodine. It has a radioactive decay half life of about eight days. Its uses are mostly medical and pharmaceutical.

Iodine 131 exposure during childhood increases risk of developing thyroid cancer

Alan H. Lockwood, MD, professor of neurology and nuclear medicine in the University at Buffalo's School of Medicine and Biomedical Sciences calls the Japanese Health Ministry's advice not to give tap water to infants "prudent."

24 Mar 2011

Experts issue joint statement to help Americans understand radiation-related health risks

The growing concern surrounding the release of radiation from an earthquake and tsunami-stricken nuclear complex in Japan has raised fears of radiation exposure to populations in North America from the potential plume of radioactivity crossing the Pacific Ocean.

19 Mar 2011

Radiations from Japanese nuclear plants do not pose immediate risk to the U.S.

Airborne radiation from a meltdown at Japanese nuclear plants poses no immediate risk to the continental United States, say University of Maryland public health and atmospheric scientists.

17 Mar 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

Probactive Biotech, Inc., a Garden Grove, California-based corporation, has entered into an agreement with Dalat Nuclear Research Institute to co-develop a number of cancer drugs, utilizing combinations of antitumor antibodies and antitumor radioactive compounds. Antitumor antibodies have the ability to take antitumor compounds directly to the tumor sites within the body.

22 Jun 2010

Immunomedics reports encouraging results from TF2 Phase I studies for colorectal cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that TF2, a proprietary bispecific antibody, has shown selective tumor localization and minimal normal tissue retention in two early Phase I studies in patients with colorectal cancer.

8 Jun 2010

AACE, AME and ETA jointly publish guidelines for diagnosis and management of thyroid nodules

Three of the world's most respected medical associations for the treatment of thyroid disease recently issued joint guidelines for the diagnosis and management of thyroid nodules. The American Association of Clinical Endocrinologists, the Associazione Medici Endocrinologi and European Thyroid Association jointly published the guidelines online this week, and the executive summary will be published in the next issue of their respective journals.

20 May 2010

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.

9 Dec 2009

Revised Management Guidelines for diagnosing and treating thyroid cancer released

The American Thyroid Association has released new, revised Management Guidelines for the diagnosis and treatment of patients with thyroid nodules and thyroid cancer. The new guidelines are published in Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com).

6 Nov 2009

Pazopanib shows promise for aggressive thyroid cancer

A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates.

17 May 2009

Monoclonal antibody cancer therapy

The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects.

6 Apr 2009

Molecular imaging enables earlier, individualized treatment of thyroid cancer

In a study to determine the diagnostic value of molecular imaging in nodal staging of patients with thyroid cancer, researchers were able for the first time to accurately distinguish between cancerous cells in regional lymph nodes and normal residual thyroid tissue directly after surgery.

5 Jan 2009

Discovery of molecule that targets brain tumors

UC Davis Cancer Center researchers report today the discovery of a molecule that targets glioblastoma, a highly deadly form of cancer.

30 Dec 2008

Thyroid cancer drug given expanded approval by FDA

The U.S. Food and Drug Administration (FDA) has given expanded approval for a drug used to treat thyroid cancer.

19 Dec 2007

FDA tightens potency specifications to ensure thyroid drugs last

The U.S. Food and Drug Administration is tightening the potency specifications for levothyroxine sodium, used to treat underactive thyroid glands and other thyroid conditions, to ensure the drug retains its potency over its entire shelf life.

4 Oct 2007

Percutaneous ethanol injection helps manage bone metastasis in thyroid cancer patients

Percutaneous ethanol injection (PEI), an injection of ethanol (alcohol) through the skin directly into a bone tumor to kill cancer cells, may be a valuable ancillary treatment for thyroid cancer patients whose cancer has spread to the bone.

5 Jun 2007

In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles

In an attempt to determine what factors make one nanoparticle better than another at targeting tumors, a team of investigators in Korea have conducted a systematic tumor-targeting study of a variety of self-assembling nanoparticles.

18 Dec 2006

Radioactive treatment can set off security alarms

According to a new case report patients receiving radioactive isotopes should be warned that they may trigger radiation alarms for several weeks after the treatment has been completed.

7 Aug 2006

Patients receiving treatment with radioisotopes may trigger security alarms

Patients receiving treatment with radioisotopes should be warned that they may trigger radiation alarms, say doctors in this week's British Medical Journal.

3 Aug 2006

rhTSH combined with radiation therapy successfully destroys remaining thyroid tissue

A multicenter international study, including Johns Hopkins, has found that after surgery for thyroid cancer, giving genetically engineered human thyroid-stimulating hormone (rhTSH) before radioiodine treatment avoids the previous need to stop thyroid replacement therapy and the miserable side effects that go with it.

9 Jan 2006